Company Overview of Igenica, Inc.
Igenica, Inc., a biotherapeutic company, engages in the discovery and development of antibodies and antibody-drug conjugates for the treatment of cancer. The company focuses on the development of immunotherapies, functional antibodies directed to the tumor, and antibody-drug conjugates for the treatment of cancer. It provides IGN523, a humanized monoclonal antibody for the treatment of various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, an immune checkpoint target that plays a complimentary role in the tumor micro-environment to other known immune checkpoints. Igenica, Inc. has a strategic oncology research agreement with MedImmune. The company was founded i...
863A Mitten Road
Burlingame, CA 94010
Founded in 2008
Key Executives for Igenica, Inc.
Co-Founder and Vice President of Research
Co-Founder, Chairman of Scientific Advisory Board and Director
Compensation as of Fiscal Year 2016.
Igenica, Inc. Key Developments
Igenica, Inc. Presents at BBC BD Boston, Mar-09-2016 10:30 AM
Jan 1 16
Igenica, Inc. Presents at BBC BD Boston, Mar-09-2016 10:30 AM. Venue: The Westin Copley Place, 10 Huntington Avenue, Boston, MA 02116, United States. Speakers: John K. Celebi, Chief Business Officer.
Igenica Biotherapeutics Signs Oncology Research Deal with MedImmune
Oct 28 15
Igenica Biotherapeutics has signed an oncology research agreement with AstraZeneca's subsidiary MedImmune. The companies will assess the potential of antibody-drug conjugates (ADCs) targeting Surface Antigen in Leukemia (SAIL). SAIL is a novel cell surface protein with high prevalence of expression in several hematologic malignancies and solid tumors. Preclinical data have supported the selective targeting of tumors expressing SAIL with ADCs. Igenica will provide its anti-SAIL antibodies, including IGN786, and its SNAP ADC drug linker, while MedImmune will contribute its anti-tumor payload. Both the companies will then jointly investigate the resulting novel ADC in preclinical studies. MedImmune will have an option to an exclusive worldwide license to anti-SAIL antibodies and antibody-drug conjugates that arise from the partnership. Igenica will have an exclusive option fee. If MedImmune exercises its option, the company will also receive an upfront license fee, clinical, regulatory and commercialization milestones, and royalties on net sales. The development and commercialization costs will be funded by MedImmune under a license agreement.
Igenica Biotherapeutics, Inc. Presents at BIO-Europe 2015, Nov-02-2015
Oct 1 15
Igenica Biotherapeutics, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|